217 related articles for article (PubMed ID: 22851617)
1. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
Joshi S; Gudi G; Menon VCA; Tandon M; Joshi V; Suryawanshi S; Barkate H; Sawant N; Katare S; Siddique W
Clin Pharmacokinet; 2020 Mar; 59(3):349-357. PubMed ID: 31583610
[TBL] [Abstract][Full Text] [Related]
3. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
4. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
O'Connor-Semmes R; Walker S; Kapur A; Hussey EK; Ye J; Wang-Smith L; Tao W; Dobbins RL; Cheatham B; Wilkison WO
Drug Metab Dispos; 2015 Jul; 43(7):1077-83. PubMed ID: 25934577
[TBL] [Abstract][Full Text] [Related]
6. Regional gastrointestinal delivery of remogliflozin etabonate in humans.
O'Connor-Semmes RL; Sandefer EP; Hussey EK; Tao W; Doll WJ; Page RC; Dobbins R
Biopharm Drug Dispos; 2013 Mar; 34(2):79-86. PubMed ID: 23111980
[TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
[TBL] [Abstract][Full Text] [Related]
8. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Hussey EK; Kapur A; O'Connor-Semmes R; Tao W; Rafferty B; Polli JW; James CD; Dobbins RL
BMC Pharmacol Toxicol; 2013 Apr; 14():25. PubMed ID: 23631443
[TBL] [Abstract][Full Text] [Related]
10. Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
Shimizu K; Fujikura H; Fushimi N; Nishimura T; Tatani K; Katsuno K; Fujimori Y; Watanabe S; Hiratochi M; Nakabayashi T; Kamada N; Arakawa K; Hikawa H; Azumaya I; Isaji M
Bioorg Med Chem; 2021 Mar; 34():116033. PubMed ID: 33581390
[TBL] [Abstract][Full Text] [Related]
11. Remogliflozin Etabonate: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(10):1157-1161. PubMed ID: 31201711
[TBL] [Abstract][Full Text] [Related]
12. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Dobbins RL; O'Connor-Semmes R; Kapur A; Kapitza C; Golor G; Mikoshiba I; Tao W; Hussey EK
Diabetes Obes Metab; 2012 Jan; 14(1):15-22. PubMed ID: 21733056
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
Hussey EK; Clark RV; Amin DM; Kipnes MS; O'Connor-Semmes RL; O'Driscoll EC; Leong J; Murray SC; Dobbins RL; Layko D; Nunez DJ
J Clin Pharmacol; 2010 Jun; 50(6):623-35. PubMed ID: 20056803
[TBL] [Abstract][Full Text] [Related]
16. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
17. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Mikhail N
Expert Opin Investig Drugs; 2015; 24(10):1381-7. PubMed ID: 26288025
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
19. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.
Mohan V; Mithal A; Joshi SR; Aravind SR; Chowdhury S
Drug Des Devel Ther; 2020; 14():2487-2501. PubMed ID: 32612352
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
